Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKesson
AstraZeneca
Dow
Mallinckrodt

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Abametapir

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Abametapir?

Abametapir is an investigational drug.

There have been 5 clinical trials for Abametapir. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2014.

The most common disease conditions in clinical trials are Lice Infestations, Parasitic Diseases, and Mite Infestations. The leading clinical trial sponsors are Hatchtech Pty Ltd, Accelovance, and INC Research.

There are one hundred and thirty-eight US patents protecting this investigational drug and seven hundred and fifteen international patents.

Recent Clinical Trials for Abametapir
TitleSponsorPhase
Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice InfestationHatchtech Pty LtdPhase 2
Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationAccelovancePhase 3
Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationINC ResearchPhase 3

See all Abametapir clinical trials

Clinical Trial Summary for Abametapir

Top disease conditions for Abametapir
Top clinical trial sponsors for Abametapir

See all Abametapir clinical trials

US Patents for Abametapir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Abametapir   Start Trial Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element IDEMITSU KOSAN CO., LTD. (Chiyoda-ku, JP)   Start Trial
Abametapir   Start Trial Electronically neutral metal complexes as biological labels Rubipy Scientific, Inc. (Greely, Ontario, CA)   Start Trial
Abametapir   Start Trial Charge transporting material, organic electroluminescent element, light emitting device, display device and illumination device UDC Ireland Limited (Dublin, IE)   Start Trial
Abametapir   Start Trial Imidic acid compound having divalent anion and process for producing the same CENTRAL GLASS CO., LTD. (Yamaguchi, JP)   Start Trial
Abametapir   Start Trial Process for preparing polymers based on carbon monoxide and olefins Enichem S.p.A. (Milan, IT)   Start Trial
Abametapir   Start Trial Bipyridyls Ciba-Geigy Corp. (Ardsley, NY)   Start Trial
Abametapir   Start Trial Osmium-containing redox mediator Boehringer Mannheim Corporation (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Abametapir

Drugname Country Document Number Estimated Expiration Related US Patent
Abametapir Japan 6106680 2032-09-14   Start Trial
Abametapir Japan WO2014042265 2032-09-14   Start Trial
Abametapir World Intellectual Property Organization (WIPO) 2014042265 2032-09-14   Start Trial
Abametapir China 105492575 2033-06-18   Start Trial
Abametapir World Intellectual Property Organization (WIPO) 2014203067 2033-06-18   Start Trial
Abametapir Japan 2013243299 2032-05-22   Start Trial
Abametapir Japan 6009816 2032-05-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Harvard Business School
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.